Keywords: Ranbaxy, ANDAs, Consent decreee, USA, FDA, Daiichi Sankyo
US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree
Article | 23 August 2012
The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs) held by Indian drugmaker Ranbaxy Laboratories ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
